Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Free Cash Flow (2016 - 2025)

Haemonetics has reported Free Cash Flow over the past 17 years, most recently at $87.2 million for Q4 2025.

  • Quarterly results put Free Cash Flow at $87.2 million for Q4 2025, up 147.63% from a year ago — trailing twelve months through Dec 2025 was $308.1 million (up 211.41% YoY), and the annual figure for FY2025 was $142.4 million, down 0.82%.
  • Free Cash Flow for Q4 2025 was $87.2 million at Haemonetics, down from $106.3 million in the prior quarter.
  • Over the last five years, Free Cash Flow for HAE hit a ceiling of $106.3 million in Q3 2025 and a floor of -$33.1 million in Q2 2024.
  • Median Free Cash Flow over the past 5 years was $34.1 million (2022), compared with a mean of $32.0 million.
  • Biggest five-year swings in Free Cash Flow: tumbled 478.98% in 2021 and later skyrocketed 526.93% in 2024.
  • Haemonetics' Free Cash Flow stood at $22.6 million in 2021, then skyrocketed by 110.03% to $47.6 million in 2022, then tumbled by 131.93% to -$15.2 million in 2023, then skyrocketed by 331.92% to $35.2 million in 2024, then skyrocketed by 147.63% to $87.2 million in 2025.
  • The last three reported values for Free Cash Flow were $87.2 million (Q4 2025), $106.3 million (Q3 2025), and $13.6 million (Q2 2025) per Business Quant data.